FDA wants limits on bead size in “sprinkle delivery” drugs

By Gareth Macdonald

- Last updated on GMT

Related tags: Pharmaceutical drug, Food and drug administration

The US FDA has suggested pharmaceutical firms use a maximum bead size of 2.0mm for modified-release drugs formulated for “sprinkle” delivery to avoid problems resulting from inadvertent chewing.

The recommendation, part of draft guidelines​ issued last week, is designed to ensure that capsule-formulated drug products that are approved for mixture with soft food to aid delivery perform correctly and can be properly absorbed.

The Food and Drug Administration (FDA) said it: “Recognized the specific importance of a maximum bead size limit for modified-release products, where unintentional chewing of beads may lead to pharmacokinetic differences.”

The agency suggested that considerable “taste and performance issues” may arise from accidental chewing and that these again could result in non-compliance and decreased therapeutic efficacy.


The draft guidance also flags up bioequivalence as an area likely to be affected by differences in bead size.

For NDA submissions the agency calls on manufacturers to undertake bioavailability studies to prove that drug’s mixed with food perform in a manner consistent with non-mixed product as a condition of gaining “sprinkle” approval.

And for ANDAs said it wanted generics manufacturers to carry out bioequivalence tests for modified-release products but deemed such assessment unnecessary for immediate-release products.


The recommendations are roughly in keeping with the results of research published in the AAPS PharmSciTech Journal last year.

In the paper “Analysis of Bead Sizes for MR Capsules Labelled for Sprinkle,” lead author Laxma Nagavelli advocates a maximum bead size of 1.5mm, based on a review of 436 products approved for “sprinkle delivery” by the FDA at the time.

Related news

Related product

The Effect of Tamping Force on Bi-Layer Tablets

The Effect of Tamping Force on Bi-Layer Tablets

JRS PHARMA | 15-Aug-2020 | Technical / White Paper

Formulation of bi-layer or multi-layer tablets enables the combination of two or more drugs that may be incompatible or maybe intended for delivery at...

Follow us


View more